Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation

By sjmartinez • February 9, 2024

abatacept, acitretin, adalimumab, apremilast, biologics, brodalumab, certolizumab, cyclosporine, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, vaccination, vaccines,

Tags: abatacept, acitretin, adalimumab, apremilast, Biologics, brodalumab, certolizumab, cyclosporine, Dermatology, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, Publications, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, Vaccination, vaccines

Merkel Cell Carcinoma Masquerading as Dermatitis

Freeman M, Gates G, Ahronowitz I. Merkel Cell Carcinoma Masquerading as Dermatitis. Cureus. 2026 Sep 19;18(9):e116561. doi: 10.7759/cureus.116561. PMID: 42903405; PMCID: PMC13680730.

Ethical Implications of Patient-Requested Cessation of Mohs Micrographic Surgery with Residual Tumor

Ajmani A, Sanjeev R, Klufas T, Zhou AE, Davis JC, Grant-Kels JM. Ethical Implications of Patient-Requested Cessation of Mohs Micrographic Surgery with Residual Tumor. J[...]

Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials

McInnes IB, Stein Gold L, Bissonnette R, Lebwohl MG, Reyes-Servin O, Cafone J, Yang YW, Chakravarty SD, Iaconangelo C, Li S, Shagroni T, Lozenski K,[...]